Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026

Clinical-stage PTK7 ADC KIVU-107 and next-generation CEACAM5 ADC KIVU-305 demonstrate promising preclinical results

Apr. 15, 2026 at 4:03am

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray-style image revealing the intricate molecular structure of a cancer-fighting antibody-drug conjugate, with ghostly glowing lines and shapes conveying a sense of clinical innovation and scientific advancement.Kivu Bioscience's innovative ADC designs aim to overcome the tolerability challenges of earlier cancer therapies.San Mateo Today

Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), announced it will present new preclinical data on its lead ADC programs KIVU-107 and KIVU-305 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. The data highlights the potential of these ADCs to overcome tolerability challenges and demonstrate potent anti-tumor activity across solid tumor models.

Why it matters

Kivu Bioscience's ADC pipeline represents an important advancement in the field, as earlier ADC programs targeting PTK7 and CEACAM5 have faced limitations in efficacy and tolerability. The company's novel linker-payload technologies aim to improve safety and efficacy, potentially offering new treatment options for patients with difficult-to-treat cancers.

The details

KIVU-107 is a PTK7-targeted ADC designed to have improved tolerability compared to previous PTK7 ADCs, while KIVU-305 targets the CEACAM5 antigen and is engineered to have enhanced stability and potency. Both programs will be featured in poster presentations at AACR 2026, showcasing their strong preclinical results, including favorable pharmacokinetics, anti-tumor activity, and tolerability profiles.

  • The AACR Annual Meeting 2026 will be held from April 17-22 in San Diego.
  • Kivu Bioscience will present data on KIVU-107 and KIVU-305 on Tuesday, April 21, 2026 from 2:00 PM to 5:00 PM PT.

The players

Kivu Bioscience

A clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology.

Mohit Trikha, Ph.D.

Chief Executive Officer of Kivu Bioscience.

KIVU-107

Kivu Bioscience's clinical-stage PTK7-targeted ADC designed to have improved tolerability compared to previous PTK7 ADCs.

KIVU-305

Kivu Bioscience's next-generation CEACAM5-targeting ADC engineered to have enhanced stability and potency.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to present new data at AACR that highlight both the strength of our ADC platform and the continued advancement of our pipeline.”

— Mohit Trikha, Ph.D., Chief Executive Officer, Kivu Bioscience

“KIVU-107 has the potential to be a best-in-class PTK7-targeted ADC, designed to overcome the tolerability challenges seen with earlier programs. Our second program, KIVU-305, expands our reach into CEACAM5, reinforcing our ability to develop differentiated ADCs with improved stability, tolerability and anti-tumor activity.”

— Mohit Trikha, Ph.D., Chief Executive Officer, Kivu Bioscience

What’s next

Kivu Bioscience plans to initiate a Phase 1 clinical trial for KIVU-305 in patients with advanced solid tumors in 2026.

The takeaway

Kivu Bioscience's next-generation ADC programs, KIVU-107 and KIVU-305, demonstrate promising preclinical results that could lead to improved treatment options for patients with difficult-to-treat cancers. The company's focus on enhancing safety and efficacy through novel linker-payload technologies sets it apart in the competitive ADC landscape.